All In Biotech

Drug Trial Radar · NCT05423262

A Study of TRK-950 in Patients With Advanced Solid Tumors

A Phase I/II Study of TRK-950 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

49

Planned (sponsor's estimate)

Start

Jul 6, 2022

Primary completion

Mar 31, 2028

Study completion Mar 31, 2028

Sponsor

Lead sponsor
Toray Industries, IncIndustry
Sponsor type
Industry
First posted
Jun 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Part 1 • To determine the safety and tolerability of TRK-950 in patients with advanced solid tumors Part 2 • To determine the safety and tolerability of TRK-950 in combination with nivolumab(NIVO) in patients with advanced solid tumors eligible for NIVO therapy Part 3 • To determine the efficacy of TRK-950 in patients with advanced/recurrent unresectable melanoma, who received prior chemotherapy with dacarbazine(DTIC) and for whom no standard therapy exists

Conditions

  • Solid Tumor
  • Melanoma

Interventions

  • TRK-950Biological

    5 or 10 mg/kg administered intravenously over 60 minutes (weekly)

  • TRK-950Biological

    10 mg/kg administered intravenously over 60 minutes (weekly)

  • TRK-950Biological

    20 mg/kg administered intravenously over 60 minutes (bi-weekly)

  • NivolumabDrug

    240 mg administered intravenously over 30 minutes (bi-weekly)

  • TRK-950Biological

    10 mg/kg administered Intravenously over 60 minutes (weekly)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose-limiting toxicities (DLTs) (Part 1 and 2)Time frame: Up to Day 28
  2. Number of participants with adverse events (AEs) (Part 1 and 2)Time frame: through study completion, an average of 1 year
  3. Number of participants with adverse events of special interest (AESIs) (Part 1 and 2)Time frame: through study completion, an average of 1 year
  4. Number of participants with serious adverse events (SAEs) (Part 1 and 2)Time frame: through study completion, an average of 1 year
  5. Objective response rate (ORR) (Part 3)Time frame: Up to approximately 12 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Nagoya City University Hospital

    Nagoya, Aichi-ken, Japan · Recruiting

  • National Hospital Organization Kyushu Cancer Center

    Fukuoka, Fukuoka, Japan · Recruiting

  • Sapporo Medical University Hospital

    Sapporo, Hokkaido, Japan · Recruiting

  • Kumamoto University Hospital

    Kumamoto, Kumamoto, Japan · Recruiting

  • Shinshu University Hospital

    Matsumoto, Nagano, Japan · Recruiting

  • Niigata Cancer Center Hospital

    Niigata, Niigata, Japan · Recruiting

  • Saitama Medical University International Medical Center

    Hidaka, Saitama, Japan · Recruiting

  • Shizuoka Cancer Center

    Nagaizumi-chō, Shizuoka, Japan · Recruiting

  • National Cancer Center Hospital

    Chuo Ku, Tokyo, Japan · Recruiting

  • Keio University Hospital

    Shinjuku-Ku, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.